BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34520751)

  • 1. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis.
    Lv J; Li Q; Ma R; Wang Z; Yu Y; Liu H; Miao Y; Jiang S
    Technol Cancer Res Treat; 2021; 20():1533033821990090. PubMed ID: 33550920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis.
    Cui F; Luo P; Bai Y; Meng J
    Technol Cancer Res Treat; 2021; 20():1533033821990007. PubMed ID: 33550957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the lncRNA FGD5-AS1/miR-497-5p/PD-L1 Axis Inhibits Malignant Phenotypes in Colon Cancer (CC).
    Zhang L; Cai X; Dai Y; Chen Y; Yu J; Zhou Y
    Biomed Res Int; 2022; 2022():1133332. PubMed ID: 35845947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA ZEB1-AS1/miR-409-3p/ZEB1 feedback loop is involved in the progression of non-small cell lung cancer.
    Qu R; Chen X; Zhang C
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):450-456. PubMed ID: 30448056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC" [Chem. Biol. Interact. (2021) 109652].
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2022 Oct; 366():110083. PubMed ID: 36058132
    [No Abstract]   [Full Text] [Related]  

  • 7. LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.
    Aichen Z; Kun W; Xiaochun S; Lingling T
    Apoptosis; 2021 Jun; 26(5-6):348-360. PubMed ID: 33974163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFRL1.
    Fan Y; Li H; Yu Z; Dong W; Cui X; Ma J; Li S
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31919528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA FGD5-AS1/miR-5590-3p axis facilitates the proliferation and metastasis of renal cell carcinoma through ERK/AKT signalling.
    Yang Y; Dong MH; Hu HM; Min QH; Xiao L
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8756-8766. PubMed ID: 32964964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA FGD5-AS1 enhances osteosarcoma cell proliferation and migration by targeting miR-506-3p/RAB3D axis.
    Li C; Lin X; Zhang C; Wan L; Yin J; Wang B
    Hum Cell; 2021 Jul; 34(4):1255-1265. PubMed ID: 33891267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
    Fu J; Cai H; Wu Y; Fang S; Wang D
    Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FXR1 promotes glioma progression by downregulating microRNA-124-3p through long noncoding RNA FGD5-AS1 upregulation.
    Gong X; Huang M; Chen L; Zeng H
    Acta Neurol Belg; 2023 Aug; 123(4):1453-1464. PubMed ID: 37074635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA FGD5-AS1 promotes tumor growth by regulating MCL1 via sponging miR-153-3p in oral cancer.
    Ge C; Dong J; Chu Y; Cao S; Zhang J; Wei J
    Aging (Albany NY); 2020 Jul; 12(14):14355-14364. PubMed ID: 32675387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA TTN-AS1 drives invasion and migration of lung adenocarcinoma cells via modulation of miR-4677-3p/ZEB1 axis.
    Zhong Y; Wang J; Lv W; Xu J; Mei S; Shan A
    J Cell Biochem; 2019 Oct; 120(10):17131-17141. PubMed ID: 31173403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGD5-AS1 Inhibits Osteoarthritis Development by Modulating miR-302d-3p/TGFBR2 Axis.
    Yang Y; Sun Z; Liu F; Bai Y; Wu F
    Cartilage; 2021 Dec; 13(2_suppl):1412S-1420S. PubMed ID: 33834880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly expressed lncRNA FOXD3-AS1 promotes non-small cell lung cancer progression via regulating miR-127-3p/mediator complex subunit 28 axis.
    Zeng ZL; Zhu HK; He LF; Xu X; Xie A; Zheng EK; Ni JJ; Liu JT; Zhao GF
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2525-2538. PubMed ID: 32196603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA FGD5-AS1 contributes to cisplatin resistance in hepatocellular carcinoma via sponging microRNA-153-3p by upregulating Twinfilin Actin Binding Protein 1 (TWF1).
    Yang Y; Shi L; Zhang D; Wu D; An Y; Zhang Y; Chen X
    Bioengineered; 2021 Dec; 12(1):6713-6723. PubMed ID: 34519634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
    Zhang H; Zhu C; He Z; Chen S; Li L; Sun C
    J Exp Clin Cancer Res; 2020 Sep; 39(1):179. PubMed ID: 32891166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S; Wang K; Huang X; Zhao Z; Zhao Z
    Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.